In yesterday’s Wall Street session, Emergent BioSolutions Inc. (NYSE:EBS) shares traded at $4.54, up 11.55% from the previous session.
As of this writing, 3 analysts cover Emergent BioSolutions Inc. (NYSE:EBS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $22.00 and a low of $11.00, we find $13.50. Given the previous closing price of $4.07, this indicates a potential upside of 231.7 percent. EBS stock price is now -33.29% away from the 50-day moving average and -54.80% away from the 200-day moving average. The market capitalization of the company currently stands at $234.72M.
There are 2 analysts who have given it a hold rating, whereas 1 have given it a buy rating. Brokers who have rated the stock have averaged $15.50 as their price target over the next twelve months.
In other news, Zoon Kathryn C, Director sold 1,830 shares of the company’s stock on Jun 02. The stock was sold for $15,280 at an average price of $8.35. Upon completion of the transaction, the Director now directly owns 49,971 shares in the company, valued at $0.23 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 25, Director Zoon Kathryn C sold 1,700 shares of the business’s stock. A total of $14,246 was realized by selling the stock at an average price of $8.38. This leaves the insider owning 51,801 shares of the company worth $0.24 million. Insiders disposed of 35,549 shares of company stock worth roughly $0.16 million over the past 1 year. A total of 0.50% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EBS stock. A new stake in Emergent BioSolutions Inc. shares was purchased by PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. during the first quarter worth $1,393,000. ASSENAGON ASSET MANAGEMENT S.A. invested $432,000 in shares of EBS during the first quarter. In the first quarter, CAPITAL FUND MANAGEMENT S.A. acquired a new stake in Emergent BioSolutions Inc. valued at approximately $417,000. DARK FOREST CAPITAL MANAGEMENT LP acquired a new stake in EBS for approximately $325,000. JUMP FINANCIAL, LLC purchased a new stake in EBS valued at around $276,000 in the second quarter. In total, there are 278 active investors with 84.60% ownership of the company’s stock.
During the past 12 months, Emergent BioSolutions Inc. has had a low of $4.01 and a high of $25.49. As of last week, the company has a debt-to-equity ratio of 0.94, a current ratio of 1.10, and a quick ratio of 0.60. The fifty day moving average price for EBS is $6.7098 and a two-hundred day moving average price translates $9.9914 for the stock.
The latest earnings results from Emergent BioSolutions Inc. (NYSE: EBS) was released for Jun, 2023. According to the Drug Manufacturers – Specialty & Generic Company, earnings per share came in at -$1.06, missing analysts’ expectations of -$0.49 by -0.57. This compares to -$1.13 EPS in the same period last year. The net profit margin was -56.60% and return on equity was -48.70% for EBS. The company reported revenue of $337.9 million for the quarter, compared to $242.7 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 39.23 percent. For the current quarter, analysts expect EBS to generate $257.77M in revenue.
Emergent BioSolutions Inc.(EBS) Company Profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
